ABSTRACT
Objective To investigate the efficacy of disodium pamidronate in treatment of bone metastasis cancer .Methods 50 cases of bone metastasis cancer were divided into control group and experimental group according to different medication, 25 cases in each group.Control group was treated by chemotherapy, experimental group was treated on the basis of control group with disodium pamidronate 45 mg+0.9%sodium chloride solution 500 mL, intravenous drip.Pain maintenance time, patient pain grading and serum NTx levels were compared after treatment.ResuIts Compared with control group,pain maintenance time of experimental group was longer(P <0.05),pain level overall score was lower,NTx was lower(P <0.05). ConcIusion Disodium pamidronate can inhibit bone metastasis cancer patients with the degree of pain, reduce the levels of serum NTx.
ABSTRACT
Objective To study the efficacy of disodium pamidronate in the treatment of patients with primary hyperparathyroidism (PHPT) complicated by hypercalcemic crisis.Methods A total of 9 patients (12 cases) admitted into our hospital were diagnosed as PHPT complicated by hypercalcemic crisis.Of them,4 patients had parathyroid carcinoma,3 patients had parathyroid adenoma,2 patients had parathyroid hyperplasia.The intravenous disodium pamidronate was given for 12 times in all 9 patients.Serum calcium were monitored before and after treatment.Results Before the treatment,the serum calcium levels was 3.75 (3.66,3.99) mmol/L.On the second and third day after the treatment with disodium pamidronate,the serum calcium levels were 3.44 (2.95,3.78) mmol/L and 2.79 (2.50,3.14) mmol/L.The lowest level of serum calcium after treatment was 2.25 (2.00,2.55) mmoL/L.There were significant differences in the level of serum calcium of different days (P ＜ 0.05).On the second and third day,the change of serum calcium were 0.46 (0.10,0.88) mmol/L,0.60 (0.25,0.75) mmol/L,there were no differences.After intravenous disodium pamidronate,the serum calcium level decreased below 3.5 mmol/L in (2.27 ± 0.65) days,and were kept below 3.5mmol/L for 18.45 ± 12.30 days.Conclusions Disodium pamidronate can decrease serum calcium levels in hypercalcemic crisis caused by primary hyperparathyroidism effectively with mild adverse events.
ABSTRACT
Introdução. A osteogênese imperfeita é doença congênita rara, de origem genética, decorrente de distúrbios na síntese do colágeno tipo 1, caracterizada por graus variados de fragilidade e deformidade óssea. Objetivo. Avaliar o impacto da terapia com pamidronato sobre o número de fraturas, a dor óssea, a motricidade funcional e a prática de atividades físicas em pacientes pediátricos com osteogênese imperfeita. Método. Estudo retrospectivo dos prontuários de sessenta pacientes com osteogênese imperfeita, acompanhados no Hospital Universitário de Brasília. Foram tabelados e analisados os dados referentes ao número de pacientes com fraturas, dores ósseas, prática regular de atividades físicas e à motricidade funcional antes e depois do início da terapia com pamidronato. Resultados. Das 60 crianças avaliadas (30 do sexo feminino) com osteogênese imperfeita, 14 foram do tipo I,33 do tipo III e 13 do tipo IV. A média de idade foi 8,8 ± 4,5 anos e média de idade ao diagnóstico, 3,1 ± 4,1 anos.Desses, 55 ingressaram no protocolo para recebimento do pamidronato. Depois do início da terapia, o número de doentes que tiveram fraturas reduziu-se de 55 para 17; o número de casos com dores ósseas constantes decresceu de 39 para 8; o de pacientes com prática regular de atividade física subiu de 12 para 38 e todos tiveram melhora damotricidade funcional. Todas essas diferenças foram estatisticamente ignificativas. Conclusão. O uso de pamidronato está relacionado à diminuição estatisticamente significativa de fraturas e de dores ósseas, à melhora da motricidade funcional e à regularidade de bons desempenhos físicos em indivíduos com osteogênese imperfeita, com repercussão positiva em sua integração social.
Introduction. Osteogenesis imperfecta is a rare congenital disease, of genetic inheritance, secondary to disturbanceson type 1 collagen synthesis, and characterized by a wide spectrum of bone fragilities and deformities. Objective. To evaluate the impact of pamidronate therapy on the number of fractures, bone pain complaints, functional motor mobility and on the practice of physical activities among pediatric patients with osteogenesis imperfecta. Method. Retrospective study of the records from the sixty patients with osteogenesis imperfecta followed at Hospital Universitário de Brasília. The data relating to the number of patients presenting fractures, bone pain andwith customary physical activities and to their functional mobility before and after pamidronate therapy were set and analyzed. Results. From the 60 children (30 females) with osteogenesis imperfecta, 14 were type I, 33 type III and 13 type IV. Mean age was 8.8 ± 4.5 years and mean age at diagnosis was 3.1 ± 4.1 years. Fifty-five patients were admitted to the pamidronate protocol. After the therapy has started, the number of patients presenting fractures decreased from55 to 17, presenting constant bone pain went from 39 to 8, with customary physical activities increased from 12 to 38 and all of them presented optimized functional motor mobility. All these differences were statistically significant. Conclusion. The use of pamidronate is related to a statistically significant decrease in fractures and bone pains and improvement on functional mobility and on regular practice of physical activity among patients with osteogenesis imperfecta, leading to a positive repercussion on their social integration.